Zydus Lifesciences Share Price Today (ZYDUSLIFE)
TODAY IN ONE LINE
ZYDUSLIFE fell 1.9% on average volume, lagging Nifty's -0.8% move, supported by recent strong earnings.
With a market cap of ₹1.12 L Cr., it trades at a P/E of 22.82. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Zydus Lifesciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 16.2% and Profit up 21.9%
- ●High Capital EfficiencyROCE of 21.1% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 21.2%
- ●Healthy Operating MarginsOPM is structurally strong at 31.2%
- ●High Promoter HoldingPromoters hold 75.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Zydus Lifesciences News
What changed recently?
Recent events, corporate actions, and announcements.
Zydus Lifesciences Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Zydus Lifesciences Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Zydus Lifesciences Ltd trades at a P/E of 22.82× and P/B of 4.24×, against the Healthcare sector median P/E of 40.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Zydus Lifesciences Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Zydus Lifesciences Ltd — derived from the live tape, not yesterday's close.
Zydus Lifesciences Ltd last traded at ₹1,121 with an intraday range of ₹1,113–₹1,138.1 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1121.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1185.27 | +64.27 | +5.73% |
| R3 | 1160.17 | +39.17 | +3.49% |
| R2 | 1149.13 | +28.13 | +2.51% |
| R1 | 1135.07 | +14.07 | +1.25% |
| PIVOT | 1124.03 | 3.03 | 0.27% |
| CURRENT | 1121.00 | — | — |
| S1 | 1109.97 | -11.03 | -0.98% |
| S2 | 1098.93 | -22.07 | -1.97% |
| S3 | 1084.87 | -36.13 | -3.22% |
| S4 | 1059.77 | -61.23 | -5.46% |
ZYDUSLIFE is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1113–₹1138.1
Trading Below opening range, showing Bearishness
Zydus Lifesciences Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Zydus Lifesciences Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Zydus Lifesciences Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.12 L Cr. and reported EPS of ₹50.10.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 23,242 | 27,148 ▲ 16.8% |
| Sales Growth YoY %Derived | 18.90% | 16.81% |
| Other Income | 270 | 510 ▲ 89.1% |
| Total Income | 23,511 | 27,658 ▲ 17.6% |
| 6,338 | 7,293 ▲ 15.1% | |
| Gross ProfitDerived | 16,904 | 19,856 ▲ 17.5% |
| Gross Margin %Derived | 72.73% | 73.14% |
| 9,845 | 11,381 ▲ 15.6% | |
| EBITDA (Operating Profit)Derived | 7,059 | 8,475 ▲ 20.1% |
| OPM %Derived | 30.37% | 31.22% |
| 862 | 1,330 ▲ 54.3% | |
| Profit Before Tax (PBT) | 6,027 | 6,621 ▲ 9.9% |
| 1,412 | 1,595 ▲ 12.9% | |
| Effective Tax %Derived | 23.43% | 24.09% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 4,673 | 5,124 ▲ 9.6% |
| Less: Non-controlling Interests | 4,526 | 84 ▼ 98.2% |
| Net Profit (Owner's PAT)Derived | 147 | 5,040 ▲ 3326.2% |
| Net Profit Margin %Derived | 0.63% | 18.56% |
| PAT Growth YoY %Derived | 29.83% | 3,326.24% |
| Earnings Per Share (EPS ₹) | 1.46 | 50.09 ▲ 3330.8% |
| Diluted Shares Outstanding (Cr) | 101 | 101 ▲ 0.0% |
| Share of Profit from Associates/JVs | 58 | 97 ▲ 68.0% |
| Other Comprehensive Income (Net of Tax) | -100 | -775 ▼ 674.8% |
| Total Expenses (incl. D&A & Interest) | 17,484 | 21,037 ▲ 20.3% |
| Material Cost % of RevenueDerived | 18.82% | 18.82% |
| Employee Cost % of RevenueDerived | 15.84% | 16.27% |
| Other Cost % of RevenueDerived | 26.52% | 25.65% |
| Interest Coverage (x)Derived | 37.03x | 16.10x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 11,936 | 13,166 ▲ 10.3% | 14,253 ▲ 8.3% | 15,102 ▲ 6.0% | 15,265 ▲ 1.1% | 17,237 ▲ 12.9% | 19,547 ▲ 13.4% | 23,242 ▲ 18.9% | 27,148 ▲ 16.8% | |
| Sales Growth YoY %Derived | — | 10.30% | 8.26% | 5.96% | 1.08% | 12.92% | 13.40% | 18.90% | 16.81% | |
| Other Income | 113 | 201 ▲ 77.7% | 114 ▼ 43.4% | 37 ▼ 67.3% | 225 ▲ 504.0% | 187 ▼ 17.0% | 284 ▲ 52.3% | 270 ▼ 5.1% | 510 ▲ 89.1% | |
| Total Income | 12,050 | 13,367 ▲ 10.9% | 14,367 ▲ 7.5% | 15,139 ▲ 5.4% | 15,490 ▲ 2.3% | 17,424 ▲ 12.5% | 19,832 ▲ 13.8% | 23,511 ▲ 18.6% | 27,658 ▲ 17.6% | |
4,154 | 4,716 ▲ 13.6% | 4,920 ▲ 4.3% | 5,210 ▲ 5.9% | 5,545 ▲ 6.4% | 6,310 ▲ 13.8% | 6,228 ▼ 1.3% | 6,338 ▲ 1.8% | 7,293 ▲ 15.1% | ||
| Gross ProfitDerived | 7,783 | 8,449 ▲ 8.6% | 9,333 ▲ 10.5% | 9,892 ▲ 6.0% | 9,720 ▼ 1.7% | 10,927 ▲ 12.4% | 13,319 ▲ 21.9% | 16,904 ▲ 26.9% | 19,856 ▲ 17.5% | |
| Gross Margin %Derived | 65.20% | 64.18% | 65.48% | 65.50% | 63.67% | 63.39% | 68.14% | 72.73% | 73.14% | |
4,935 | 5,476 ▲ 11.0% | 6,550 ▲ 19.6% | 6,551 ▲ 0.0% | 6,379 ▼ 2.6% | 7,067 ▲ 10.8% | 7,935 ▲ 12.3% | 9,845 ▲ 24.1% | 11,381 ▲ 15.6% | ||
| EBITDA (Operating Profit)Derived | 2,848 | 2,973 ▲ 4.4% | 2,783 ▼ 6.4% | 3,341 ▲ 20.0% | 3,341 ▼ 0.0% | 3,860 ▲ 15.5% | 5,384 ▲ 39.5% | 7,059 ▲ 31.1% | 8,475 ▲ 20.1% | |
| OPM %Derived | 23.86% | 22.58% | 19.53% | 22.12% | 21.88% | 22.39% | 27.54% | 30.37% | 31.22% | |
630 | 792 ▲ 25.8% | 675 ▼ 14.8% | 683 ▲ 1.3% | 953 ▲ 39.4% | 248 ▼ 73.9% | 831 ▲ 234.6% | 862 ▲ 3.7% | 1,330 ▲ 54.3% | ||
| Profit Before Tax (PBT) | 2,331 | 2,382 ▲ 2.2% | 1,495 ▼ 37.2% | 2,285 ▲ 52.8% | 2,838 ▲ 24.2% | 2,590 ▼ 8.8% | 4,809 ▲ 85.7% | 6,027 ▲ 25.3% | 6,621 ▲ 9.9% | |
564 | 530 ▼ 6.0% | 320 ▼ 39.7% | 147 ▼ 54.0% | 512 ▲ 247.6% | 588 ▲ 14.9% | 978 ▲ 66.3% | 1,412 ▲ 44.4% | 1,595 ▲ 12.9% | ||
| Effective Tax %Derived | 24.21% | 22.26% | 21.39% | 6.44% | 18.03% | 22.70% | 20.33% | 23.43% | 24.09% | |
| Profit/Loss from Discontinued Ops | -19 | — ▲ 100.0% | — | — | 2,246 | -5 ▼ 100.2% | 23 ▲ 600.0% | — ▼ 100.0% | — | |
| Total Profit for Period | 1,810 | 1,899 ▲ 4.9% | 1,204 ▼ 36.6% | 2,185 ▲ 81.4% | 4,618 ▲ 111.4% | 2,092 ▼ 54.7% | 3,973 ▲ 89.9% | 4,673 ▲ 17.6% | 5,124 ▲ 9.6% | |
| Less: Non-controlling Interests | 35 | 50 ▲ 44.2% | 28 ▼ 44.3% | 51 ▲ 84.9% | 131 ▲ 154.9% | 132 ▲ 0.5% | 3,860 ▲ 2832.8% | 4,526 ▲ 17.3% | 84 ▼ 98.2% | |
| Net Profit (Owner's PAT)Derived | 1,776 | 1,849 ▲ 4.1% | 1,177 ▼ 36.4% | 2,134 ▲ 81.3% | 4,487 ▲ 110.3% | 1,960 ▼ 56.3% | 113 ▼ 94.2% | 147 ▲ 29.8% | 5,040 ▲ 3326.2% | |
| Net Profit Margin %Derived | 14.88% | 14.04% | 8.26% | 14.13% | 29.40% | 11.37% | 0.58% | 0.63% | 18.56% | |
| PAT Growth YoY %Derived | — | 4.11% | -36.36% | 81.34% | 110.32% | -56.31% | -94.22% | 29.83% | 3,326.24% | |
| Earnings Per Share (EPS ₹) | 17.35 | 18.06 ▲ 4.1% | 11.49 ▼ 36.4% | 20.84 ▲ 81.4% | 43.83 ▲ 110.3% | 19.37 ▼ 55.8% | 1.13 ▼ 94.2% | 1.46 ▲ 29.2% | 50.09 ▲ 3330.8% | |
| Diluted Shares Outstanding (Cr) | 102 | 102 ▲ 0.0% | 102 ▲ 0.0% | 102 ▲ 0.0% | 102 ▲ 0.0% | 101 ▼ 1.1% | 101 ▼ 0.6% | 101 ▲ 0.0% | 101 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 63 | 47 ▼ 25.3% | 29 ▼ 38.6% | 47 ▲ 64.6% | 46 ▼ 2.5% | 95 ▲ 104.8% | 118 ▲ 25.2% | 58 ▼ 51.2% | 97 ▲ 68.0% | |
| Other Comprehensive Income (Net of Tax) | 20 | -168 ▼ 961.5% | -301 ▼ 78.9% | 73 ▲ 124.3% | -105 ▼ 243.0% | -314 ▼ 200.9% | -200 ▲ 36.4% | -100 ▲ 50.0% | -775 ▼ 674.8% | |
| Total Expenses (incl. D&A & Interest) | 9,719 | 10,985 ▲ 13.0% | 12,872 ▲ 17.2% | 12,855 ▼ 0.1% | 12,652 ▼ 1.6% | 14,834 ▲ 17.3% | 15,023 ▲ 1.3% | 17,484 ▲ 16.4% | 21,037 ▲ 20.3% | |
| Material Cost % of RevenueDerived | 21.40% | 20.31% | 24.27% | 25.75% | 26.48% | 23.92% | 23.43% | 18.82% | 18.82% | |
| Employee Cost % of RevenueDerived | 15.54% | 16.13% | 16.94% | 16.49% | 15.95% | 16.04% | 16.05% | 15.84% | 16.27% | |
| Other Cost % of RevenueDerived | 25.81% | 25.46% | 29.01% | 26.89% | 25.84% | 24.96% | 24.54% | 26.52% | 25.65% | |
| Interest Coverage (x)Derived | 25.34x | 12.27x | 6.11x | 16.00x | 20.69x | 24.15x | 56.90x | 37.03x | 16.10x |
Zydus Lifesciences segment analysis : revenue and profit mix.
Disclosed business segments at Zydus Lifesciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Zydus Lifesciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Zydus Lifesciences Ltd.
Our AI distills the core fundamental drivers supporting Zydus Lifesciences Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Zydus Lifesciences Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Market cap ₹1.14 LCr ranks fourth among Indian pharma peers, strong scale.
ROCE 21.20% exceeds peer median, superior capital efficiency demonstrated.
Operating margin 21.66% outpaces peer average, pricing power evident.
P/E 21.97x well below peer median 38.97x, attractive valuation offered.
Promoter holding 75.01% ensures stable governance and long-term alignment.
Key Risks.
Latest quarterly EPS grew 8.70% YoY despite competitive pressures.
Net debt ₹20,444 Cr rising significantly, increasing leverage risk.
Capex intensity high at ₹8,675 Cr quarterly, constraining free cash flow.
Working capital swings volatile; Q3 2025 changes ₹-30,225 Cr, operational drag.
Operating cash flow ₹1,124 Cr in Q3 2025 down from prior periods.
Flip Conditions.
Valuation risk. a P/E above 30 (~0.7× the sector multiple of 40.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 16% would indicate weaker capital compounding.
Zydus Lifesciences Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Zydus Lifesciences Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Zydus Lifesciences Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Zydus Lifesciences Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Zydus Lifesciences Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Zydus Lifesciences Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Zydus Lifesciences Ltd stood at 57.8% of traded volume, against a 20-day average of 52.1%.
Zydus Lifesciences announcements: results, concalls, ratings, M&A.
Filings Zydus Lifesciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Zydus Lifesciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 296 documents below.
News Verification
The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts…
News Verification
The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts…
Copy of Newspaper Publication
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Zydus Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2026
Copy of Newspaper Publication
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Zydus Lifesciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Zydus Lifesciences has declared, sequenced by announce and record date.
Zydus Lifesciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Zydus Lifesciences Ltd: business, sector, key facts.
What Zydus Lifesciences Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Zydus Lifesciences Ltd operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ZYDUSLIFE, BSE: 532321.
Zydus Lifesciences Limited is a global pharmaceutical company with a diverse portfolio spanning research, development, manufacturing, marketing, and distribution of a wide range of healthcare products. Its operations extend across India, the United States, and other international markets, solidifying its position as a significant player in the industry.
The company's business is structured into two primary segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment focuses on the production and sale of finished dosage forms, including generic drugs, branded generics, and specialty formulations such as biosimilars and vaccines. They also manufacture active pharmaceutical ingredients (APIs) and cater to various therapeutic areas, encompassing pain management, neurology, metabolic disorders, and liver diseases. A strong pipeline of biological products is under development, targeting oncology, autoimmune diseases, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses.
Complementing its pharmaceutical offerings, the Consumer Products segment encompasses a portfolio of well-known brands such as Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil. These brands cater to various consumer wellness needs, demonstrating Zydus Lifesciences' commitment to holistic healthcare solutions.
Beyond its core pharmaceutical and consumer product businesses, Zydus Lifesciences also engages in other activities, including investments in related sectors, animal health and veterinary products, pharmacy retail ventures, and manpower supply and administration. This diversification strategy reflects a commitment to expanding its reach and influence within the broader healthcare ecosystem.
Founded in 1952 and headquartered in Ahmedabad, India, the company, formerly known as Cadila Healthcare Limited, rebranded to Zydus Lifesciences Limited in 2022. It operates as a subsidiary of Zydus Family Trust, reflecting its long-standing commitment to family-led stewardship and its history in the pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Zydus Lifesciences Ltd (ZYDUSLIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Zydus Lifesciences Ltd (ZYDUSLIFE)?
The current share price of Zydus Lifesciences Ltd (ZYDUSLIFE) is ₹1,121. Today, the stock has declined by ₹22.10 (1.93%), trading in a range of ₹1,113 to ₹1,138.1. The stock opened at ₹1,138 with a trading volume of 8,95,711 shares.
02Is Zydus Lifesciences Ltd stock a good investment for long-term?
Zydus Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,11,994.74 crores, P/E ratio of 22.82, ROE of 21.20%, and ROCE of 21.10%. The dividend yield stands at 0.09%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Zydus Lifesciences Ltd stock?
The 52-week high price of Zydus Lifesciences Ltd (ZYDUSLIFE) is ₹1,181.5, while the 52-week low is ₹835.5. Currently trading at ₹1,121, the stock is 82.5% away from its 52-week low and 5.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Zydus Lifesciences Ltd stock at the current price?
Whether to buy Zydus Lifesciences Ltd stock at ₹1,121 depends on multiple factors. The stock is currently trading with a P/E ratio of 22.82 and P/B ratio of 4.24. Today's performance shows a loss of 1.93%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Zydus Lifesciences Ltd and when is the next dividend?
Zydus Lifesciences Ltd offers a dividend yield of 0.09%, which means for every ₹100 invested at the current price of ₹1,121, you can expect to receive approximately ₹0.09 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd's key financial metrics include: P/E Ratio: 22.82, P/B Ratio: 4.24, ROE: 21.20%, ROCE: 21.10%, Dividend Yield: 0.09%, EPS: ₹50.10, Book Value: ₹269, and Debt-to-Equity: 0.46. The company's market cap stands at ₹1,11,994.74 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Zydus Lifesciences Ltd stock performing today in the market?
Zydus Lifesciences Ltd stock opened at ₹1,138 and is currently trading at ₹1,121, showing a decline of ₹22.10 (1.93%). The intraday high is ₹1,138.1 and low is ₹1,113. The trading volume stands at 8,95,711 shares, indicating moderate market participation today.
08What is the P/E ratio of Zydus Lifesciences Ltd and what does it indicate?
Zydus Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 22.82, which means investors are willing to pay ₹22.82 for every ₹1 of earnings. With an EPS of ₹50.10, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Zydus Lifesciences Ltd (ZYDUSLIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.